VIVOBIOTVivo Bio Tech Limited
Pharma · Biotechnology · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Vivo Bio Tech Limited provides drug development and discovery services to pharmaceutical and biotech companies worldwide. The company offers services in the areas of in vivo and in vitro toxicity studies, pharmacological investigations, pharmacokinetic and toxic kinetic studies, genotoxicity screening, and analytical services. It also supplies SPF lab animals; breeds and distributes rodent models; and offers custom rodent models, and stem cell products, as well as lab animal diets. In addition, the company provides regulatory and non-regulatory IND preclinical development services; screening and evaluating molecules for various pharmacological properties; and designs and develops of syngeneic / xenograft models for evaluation of anti-cancer agents' evaluation. The company was formerly known as Sunshine Factors & Exports Limited and changed its name to Vivo Bio Tech Limited in September 2002. Vivo Bio Tech Limited was incorporated in 1987 and is based in Hyderabad, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on VIVOBIOT — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why avoid
- • Overall evidence is weak (AlgoScore 23/100)
- • Profit growth: -89.2% YoY
- • ROE: -1.8%
- • RSI: 35
- • MACD: bearish
Bull case
- • Debt/Equity: 0.72
- • Promoter holding: 63.1%
- • Trend strength (ADX): 43
Bear case
- • Profit growth: -89.2% YoY
- • ROE: -1.8%
- • RSI: 35
- • MACD: bearish
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Weak fundamentals — technical strength may not sustain
- • Momentum is fading versus the broader market
- • Profit growth: -89.2% YoY
- • ROE: -1.8%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹1.44). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.